Pekka Raatikainen

Learn More
AIMS The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) trial assessed the long-term efficacy of an initial strategy of radiofrequency ablation (RFA) vs. antiarrhythmic drug therapy (AAD) as first-line treatment for patients with PAF. In this substudy, we evaluated the effect of these treatment(More)
A mong patients with atrial fibrillation (AF), women tend to be at higher risk of stroke than men, 1–6 even after adjustment for baseline comorbid conditions and vitamin K antagonist treatment. 7,8 Female sex has therefore been incorporated in stroke risk stratification schemes, such as CHA 2 DS 2-VASc 9 and is specified in international guidelines for(More)
AIM The aim of this prospective substudy was to estimate the cost-effectiveness of treating paroxysmal atrial fibrillation (AF) with radiofrequency catheter ablation (RFA) compared with antiarrhythmic drugs (AADs) as first-line treatment. METHODS AND RESULTS A decision-analytic Markov model, based on MANTRA-PAF (Medical Antiarrhythmic Treatment or(More)
OBJECTIVES Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) explored the impact of gender, risk factors and anticoagulant (AC) treatment on 1-year outcomes in patients with non-valvular atrial fibrillation (NVAF). DESIGN GARFIELD-AF is a prospective non-interventional registry. SETTING Investigator sites (n=1048) are(More)
  • 1